Expertise in the pharmaceutical development of rare cannabinoids
InMed is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates to treat several diseases with high unmet medical needs.
Programs for skin and ocular disease
Two of InMed’s most advanced programs focus on rare cannabinoid formulations for skin and ocular diseases. Cannabinol (CBN) is the active pharmaceutical ingredient (API) in InMed’s two lead programs for epidermolysis bullosa and glaucoma. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream for epidermolysis bullosa, a devastating, rare genetic skin disease. InMed’s second program, INM-088, is a CBN-based product being developed as a topical ocular formulation for glaucoma and is currently in preclinical studies. Learn more about our programs in epidermolysis bullosa and glaucoma.
A goal to deliver safe and effective cannabinoid treatments
InMed’s preclinical studies of cannabinol (CBN) demonstrated an excellent safety profile. In preclinical studies, CBN showed the potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). The findings from these extensive studies supported the advancement of INM-755 cream as an investigational treatment for epidermolysis bullosa (EB) into Phase 1 clinical studies in healthy volunteers. Two Phase 1 studies have been completed and Clinical Trial Applications have been filed in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa.
Integrated cannabinoid manufacturing system to produce pharmaceutical-grade, bio-identical cannabinoids
While rare cannabinoids may hold tremendous potential as new treatments for diseases with high unmet medical needs, it is not economically feasible to extract and purify most of them directly from the plant due to the very low quantities available.
IntegraSynTM, InMed’s integrated cannabinoid manufacturing system, uses multiple standard pharmaceutical processes to enable the production of cannabinoids with bio-identical structures as compared to those found in nature.
The IntegraSynTM manufacturing approach has been able to achieve a level of 2g/L cannabinoid yield, a milestone that signals commercial viability and supports advancement to large-scale production.
Successful track record
InMed aims to transform patients’ lives by developing safe and effective cannabinoid-based therapeutics across a broad spectrum of diseases with high unmet medical needs.
Since our formation in 2014, we have fortified our capital position, assembled a world class leadership team with a successful track record in drug development, strengthened our potentially game-changing technologies, and advanced our novel, cannabinoid-based pipeline of drug candidates.
Today, InMed is acutely focused on building a technologically advanced cannabinoid pharmaceutical company unlike any other.
